Expand ARTL Menu
ARTL MENU

ARTL Latest Press Releases

-- December 3, 2025 --

Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models Globe Newswire 8:30 AM

-- November 12, 2025 --

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- November 4, 2025 --

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer Globe Newswire 8:30 AM

-- October 27, 2025 --

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer Globe Newswire 8:00 AM

-- October 15, 2025 --

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit Globe Newswire 9:15 AM

-- October 1, 2025 --

Artelo Biosciences Announces Closing of $2.0 Million Public Offering Globe Newswire 4:05 PM

-- September 30, 2025 --

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering Globe Newswire 8:30 AM

-- September 29, 2025 --

Artelo Biosciences Announces Proposed Underwritten Public Offering Globe Newswire 7:15 PM
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference Globe Newswire 8:30 AM

-- September 10, 2025 --

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms Globe Newswire 8:30 AM

-- September 5, 2025 --

Artelo Biosciences Announces Closing of $3.0 Million Public Offering Globe Newswire 4:05 PM

-- September 4, 2025 --

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering Globe Newswire 8:37 AM

-- September 3, 2025 --

Artelo Biosciences Announces Proposed Underwritten Public Offering Globe Newswire 4:35 PM
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results Globe Newswire 11:33 AM
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) Globe Newswire 8:45 AM

-- August 25, 2025 --

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain Globe Newswire 7:55 AM

-- August 13, 2025 --

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- August 11, 2025 --

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 Globe Newswire 9:15 AM

-- August 4, 2025 --

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset Globe Newswire 7:30 AM

-- August 1, 2025 --

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression Globe Newswire 7:45 AM
Market Data Delayed 15 Minutes